UvA-DARE (Digital Academic Repository)

Direct thrombin inhibitors [review]

Di Nisio, M.; Middeldorp, S.; Büller, H.R.

DOI

[10.1056/NEJMra044440](https://doi.org/10.1056/NEJMra044440)

Publication date

2005

Published in

The New England journal of medicine

[Link to publication](#)

Citation for published version (APA):

Di Nisio, M., Middeldorp, S., & Büller, H. R. (2005). Direct thrombin inhibitors [review]. *The New England journal of medicine*, 353(10), 1028-1040.
<https://doi.org/10.1056/NEJMra044440>

General rights

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: <https://uba.uva.nl/en/contact>, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

REVIEW ARTICLE

DRUG THERAPY

Direct Thrombin Inhibitors

Marcello Di Nisio, M.D., Saskia Middeldorp, M.D., and Harry R. Büller, M.D.

From the Department of Vascular Medicine, Academic Medical Center, Amsterdam (M.D., S.M., H.R.B.); and the Department of Medicine and Aging, School of Medicine and Aging Research Center, Gabriele D'Annunzio University Foundation, Chieti-Pescara, Italy (M.D.). Address reprint requests to Dr. Di Nisio at the Academic Medical Center, Department of Vascular Medicine F4-138, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands, or at m.dinisio@amc.uva.nl.

N Engl J Med 2005;353:1028-40.
Copyright © 2005 Massachusetts Medical Society.

DIRECT THROMBIN INHIBITORS (DTIs) ARE A NEW CLASS OF ANTICOAGULANTS that bind directly to thrombin and block its interaction with its substrates. Some DTIs — such as recombinant hirudins, bivalirudin, and ximelagatran, either alone or in combination with melagatran — have undergone extensive evaluation in phase 3 trials for the prevention and treatment of arterial and venous thrombosis. The evidence concerning the clinical applicability of other DTIs, such as argatroban and dabigatran, is limited to phase 2 studies. Four parenteral DTIs have been approved by the Food and Drug Administration (FDA) in North America: hirudin and argatroban for the treatment of heparin-induced thrombocytopenia, bivalirudin as an alternative to heparin in percutaneous coronary intervention, and desirudin as prophylaxis against venous thromboembolism in hip replacement. This review discusses FDA-approved DTIs as well as those under evaluation in phase 2 or 3 clinical trials.

MECHANISMS OF ACTION

COAGULATION CASCADE AND GENERATION OF THROMBIN

After injury to a vessel wall, tissue factor is exposed on the surface of the damaged endothelium. The interaction of tissue factor with plasma factor VII activates the coagulation cascade, producing thrombin by stepwise activation of a series of proenzymes (Fig. 1). Thrombin is central in the clotting process: it converts soluble fibrinogen to fibrin; activates factors V, VIII, and XI, which generates more thrombin; and stimulates platelets. Furthermore, by activating factor XIII, thrombin favors the formation of cross-linked bonds among the fibrin molecules, stabilizing the clot. The coagulation cascade is regulated by natural anticoagulants, such as tissue factor pathway inhibitor, the protein C and protein S system, and antithrombin, all of which help to restrict the formation of the hemostatic plug to the site of injury.

DIFFERENCES FROM HEPARINS

Thrombin-inhibiting drugs can block the action of thrombin by binding to three domains: the active site or catalytic site and two exosites (Fig. 2). Located next to the active site, exosite 1 acts as a dock for substrates such as fibrin, thereby orienting the appropriate peptide bonds in the active site. Exosite 2 serves as the heparin-binding domain.¹ Thrombin is inhibited indirectly by low-molecular-weight heparins, because these drugs strongly catalyze the function of antithrombin. A heparin–thrombin–antithrombin complex is formed in which heparin binds simultaneously to exosite 2 in thrombin and to antithrombin. Furthermore, heparin can act as a bridge between thrombin and fibrin by binding both to fibrin and exosite 2 (Fig. 2). Because both thrombin exosites are occupied within this fibrin–heparin–thrombin complex, the enzymatic activity of thrombin is relatively protected from inactivation by the heparin–antithrombin complex.²⁻⁴ Thus, heparins have a reduced capacity for the inhibition of fibrin-bound thrombin, which ap-

Figure 1. Thrombin Generation.

The activation of coagulation proceeds through a stepwise activation of proteases that eventually results in the fibrin framework. After vascular injury, tissue-factor expression by endothelial cells is a critical step in the initial formation of fibrin, whereas the activation of factors XI, IX, and VIII is important to continue the formation of fibrin. The molecule of thrombin plays a central role within the coagulation cascade. The formation of the clot is highly regulated by natural anticoagulant mechanisms that confine the hemostatic process to the site of the injury to the vessel. Most of these natural anticoagulants are directed against the generation or action of thrombin and include antithrombin and the protein C system. Solid lines denote activation pathways, and dashed lines denote inhibitory pathways.

(This figure has been corrected from the version published on September 8, 2005.)

appears to be detrimental, because active thrombin further triggers thrombus growth.

Since DTIs act independently of antithrombin, they can inhibit thrombin bound to fibrin or fibrin degradation products.³⁻⁵ Bivalent DTIs block thrombin at both the active site and exosite 1, whereas univalent DTIs bind only to the active site. The group of bivalent DTIs includes hirudin and bivalirudin, whereas argatroban, melagatran (and its oral precursor, ximelagatran), and dabigatran are univalent DTIs. Native hirudin and recombinant hirudins (lepirudin and desirudin) form an irreversible 1:1 stoichiometric complex with thrombin.⁶ In a similar way, bivalirudin, a synthetic hirudin, binds to the active site and exosite 1,⁷ but once bound, it is cleaved by thrombin, thereby restoring the active-

site functions of thrombin.⁸ Therefore, in contrast to the hirudins, bivalirudin produces only a transient inhibition of thrombin.

By interacting only with the active site, univalent DTIs inactivate fibrin-bound thrombin.^{9,10} Argatroban and melagatran (like bivalirudin) dissociate from thrombin, leaving a small amount of free, enzymatically active thrombin available for hemostatic interactions.^{11,12}

By reducing the thrombin-mediated activation of platelets, DTIs also have an antiplatelet effect.^{13,14} Since DTIs do not bind to plasma proteins, these agents should produce a more predictable response than does unfractionated heparin and should be more effective than low-molecular-weight heparins because they inhibit fibrin-bound thrombin.

PHARMACOKINETICS AND PHARMACODYNAMICS

The routes of administration, plasma half-lives, and main sites of clearance of the various DTIs are listed in Table 1. DTIs with a predominant renal clearance such as hirudin, melagatran, and dabigatran are likely to accumulate in patients with impaired

renal function.^{12,15} Although excessive anticoagulation with hirudin in patients with renal insufficiency can be managed with high-volume hemofiltration with hirudin-permeable hemodialysis membranes,¹⁵ the available data remain scarce. Studies in animals suggest that excessive plasma concentrations of melagatran can be managed by either hemodialysis or the administration of acti-

Table 1. Main Properties and Pharmacokinetic Characteristics of Direct Thrombin Inhibitors.

Characteristic	Recombinant Hirudins*	Bivalirudin (Hirulog)	Argatroban (Novastan)	Ximelagatran and Melagatran (Exanta)	Dabigatran
Route of administration	Intravenous, subcutaneous	Intravenous	Intravenous	Intravenous, subcutaneous (melagatran), oral (ximelagatran)	Oral
Plasma half-life	Intravenous, 60 min; subcutaneous, 120 min	25 min	45 min	Intravenous and subcutaneous, 2–3 hr; oral, 3–5 hr	12 hr
Main site of clearance	Kidney	Kidney, liver, other sites	Liver	Kidney	Kidney

* Recombinant hirudins include lepirudin (Refludan) and desirudin (Iprivask).

vated prothrombin complex concentrates.¹² Since patients with severe renal impairment have been excluded from the clinical trials, the safety of DTIs that are predominantly cleared by the kidneys remains to be established.

Bivalirudin is only partially excreted by the kidneys, as hepatic metabolism and proteolysis at other sites also contribute to its metabolism.¹⁶ However, the half-life of bivalirudin is prolonged with severe renal impairment, and dose adjustments are needed.¹⁷

Argatroban is predominantly cleared by hepatic metabolism and requires dose adjustments in patients with hepatic dysfunction.¹⁸ The use of aspirin does not appear to influence the plasma concentrations of DTIs.^{19,20}

STUDIES IN ARTERIAL THROMBOSIS

ACUTE CORONARY SYNDROMES WITH OR WITHOUT PERCUTANEOUS CORONARY INTERVENTION

Patients with acute coronary syndromes (acute myocardial infarction, either with or without ST-segment elevation, and unstable angina) remain at risk for recurrent myocardial ischemia, despite treatment with aspirin, clopidogrel, and heparin.^{21,22} The role of DTIs in the management of acute coronary syndromes was reviewed by the Direct Thrombin Inhibitor Trialists' Collaborative Group in a meta-analysis of data on individual patients.²³ Eleven randomized trials were pooled, providing a total of 35,970 patients who were assigned to receive either DTIs or unfractionated heparin from 24 hours up to 7 days and then were followed for at least 30 days. As compared with heparin, DTIs reduced the incidence of the composite outcome of death and myocardial infarction both at the end of treatment and at 30 days (Table 2). The difference in risk ap-

peared to be due mainly to a significant reduction in myocardial infarction, without a significant effect on death. The analysis by agent revealed that benefits were similar for hirudin and bivalirudin, whereas a nonsignificant, small increase in the risk of death or myocardial infarction was observed with univalent DTIs. Serious bleeding occurred less frequently among patients receiving DTIs than among those receiving heparin, but there was substantial heterogeneity for this outcome. Serious bleeding occurred more frequently with hirudin than with heparin but less often with bivalirudin and univalent inhibitors. The data on univalent DTIs should be interpreted with caution owing to the rather small number of events and the fact that these results are derived from dose-finding studies, with all dosage groups combined.

In 2001, the data from another randomized clinical trial in acute coronary syndromes became available.²⁴ In this study, patients with myocardial infarction characterized by ST-segment elevation were randomly assigned to receive either bivalirudin or unfractionated heparin combined with streptokinase.²⁴ No difference was observed in the primary outcome of 30-day mortality between the two treatment groups, although a benefit of bivalirudin was observed for the secondary outcome of reinfarction within 96 hours. In contrast to the results of the meta-analysis, rates of serious bleeding were not lower with bivalirudin.

Some aspects regarding the role of DTIs in acute coronary syndromes require comment. In the trials reviewed in the meta-analysis²³ and in the Hirulog and Early Reperfusion or Occlusion 2 (HERO-2) study,²⁴ DTIs have been compared with unfractionated heparin. However, several analyses have suggested that low-molecular-weight heparin may be superior to unfractionated heparin in patients with

Table 2. Clinical Studies Comparing Direct Thrombin Inhibitors with Control Therapy in Patients with Coronary Syndromes (with or without Percutaneous Coronary Intervention) or Atrial Fibrillation.*

Study	Diagnosis or Treatment	No. of Patients	DTI Regimen	Control Treatment	Major Efficacy Outcomes	Percentage of Patients with a Major Efficacy Outcome	Serious Bleeding (percentage)
Short-term treatment of coronary artery disease							
Direct Thrombin Inhibitor Trialists' Collaborative Group ²³ study	Acute coronary syndromes with or without percutaneous coronary intervention	35,970	Hirudin, bivalirudin, argatroban, efgatran	Unfractionated heparin	Death or myocardial infarction at 30 days	Combined DTIs, 7.4; unfractionated heparin, 8.2	Combined DTIs, 1.9; unfractionated heparin, 2.3
HERO-2 ²⁴	Myocardial infarction with ST elevation	17,073	Bivalirudin at 0.25 mg/kg intravenously, followed by 0.5 mg/kg/hr for 12 hr and then 0.25 mg/kg/hr for 36 hr	Unfractionated heparin for 48 hr	Death at 30 days	Bivalirudin, 10.8; unfractionated heparin, 10.9	Bivalirudin, 0.7; unfractionated heparin, 0.5
REPLACE-2 ²⁵	Percutaneous coronary intervention	6,010	Bivalirudin at 0.75 mg/kg intravenous bolus, followed by 1.75 mg/kg/hr for duration of procedure	Unfractionated heparin plus GPIIb/IIIa inhibitors for 12–18 hr	Death, myocardial infarction, urgent repeat revascularization, or serious bleeding	Bivalirudin, 9.2; unfractionated heparin, 10.0	Bivalirudin, 2.4; unfractionated heparin, 4.1
Long-term treatment of coronary artery disease							
ESTEEM ²⁶	Myocardial infarction with or without ST elevation	1,883	Ximelagatran at 24 mg, 36 mg, 48 mg, or 60 mg twice daily for 6 mo	Placebo twice daily for 6 mo	Death from any cause, nonfatal myocardial infarction, or severe recurrent ischemia	Combined ximelagatran, 12.7; placebo, 16.3	Combined ximelagatran, 2; placebo, 1
Atrial fibrillation							
SPORTIF III ²⁷	Nonvalvular atrial fibrillation	3,407	Ximelagatran at 36 mg twice daily for a mean of 17 mo	Warfarin for a mean of 17 mo	All strokes or systemic embolism	Ximelagatran, 2.3; warfarin, 3.3	Ximelagatran, 1.7; warfarin, 2.4
SPORTIF V ²⁸	Nonvalvular atrial fibrillation	3,922	Ximelagatran at 36 mg twice daily for a mean of 20 mo	Warfarin for a mean of 20 mo	All strokes or systemic embolism	Ximelagatran, 2.6; warfarin, 1.9	Ximelagatran, 3.2; warfarin, 4.3

* DTI denotes direct thrombin inhibitor, HERO-2 Hirulog and Early Reperfusion or Occlusion 2, REPLACE-2 Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiogram to Reduced Clinical Events 2, ESTEEM Efficacy and Safety of the Oral Direct Thrombin Inhibitor Ximelagatran in Patients with Recent Myocardial Damage, and SPORTIF Stroke Prevention Using an Oral Thrombin Inhibitor in Atrial Fibrillation.

unstable angina and myocardial infarction.²⁹⁻³¹ Moreover, aggressive antiplatelet therapy has become the standard treatment in acute coronary syndromes, and the role of DTIs has not been established in the setting of the combined use of aspirin and clopidogrel, as well as glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors.

Therefore, hirudin is an unattractive alternative for the treatment of patients with acute coronary syndromes, given the lack of a clear efficacy benefit, the observed increase in bleeding, and the higher cost as compared with unfractionated heparin. In a similar manner, bivalirudin does not appear to be more efficacious or safer than unfractionated heparin and cannot be recommended in this setting.

PERCUTANEOUS CORONARY INTERVENTION

The meta-analysis mentioned above²³ suggested that the prespecified subgroup of patients undergoing percutaneous coronary intervention had no significant efficacy benefit, but the incidence of serious bleeding was less with hirudin and bivalirudin than with unfractionated heparin.

Bivalirudin was compared with heparin during coronary angioplasty for unstable or postinfarction angina. Initial results suggested that there was a benefit,³² a finding that was supported in a longer-term follow-up using an intention-to-treat analysis.³³ The combined outcome of death, myocardial infarction, and revascularization at 7 and 90 days occurred less frequently with bivalirudin, mainly owing to an effect on the need for revascularization. At 90 days, serious bleeding was significantly reduced in the bivalirudin group (3.7 percent vs. 9.3 percent).³³

The meta-analysis²³ pooled data from trials that were conducted before the introduction of newer therapies such as intracoronary stenting and the use of GPIIb/IIIa inhibitors. In the Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiomax to Reduced Clinical Events 2 (REPLACE-2) study, patients undergoing urgent or elective percutaneous coronary intervention were randomly assigned to receive unfractionated heparin plus GPIIb/IIIa inhibitors or to receive bivalirudin to which GPIIb/IIIa inhibitors were added only if complications occurred during the procedure.²⁵ Aspirin was prescribed to all patients, and the use of clopidogrel was encouraged. The composite efficacy and safety outcome of death, myocardial infarction, urgent repeat revascularization, and serious bleeding was not significantly different between

the two groups. However, the use of bivalirudin was associated with a lower rate of serious bleeding. GPIIb/IIIa inhibitors were used in only 7.2 percent of the bivalirudin recipients, which may have contributed to the lower costs associated with this approach.³⁴ The composite outcome remained not significantly different at six months³⁵ and was not affected by concomitant clopidogrel treatment.³⁶ A subanalysis of this trial confirmed the similar efficacy and the lower incidence of bleeding for bivalirudin, regardless of renal function.³⁷

In summary, bivalirudin appears to be safer than heparin in patients undergoing percutaneous coronary intervention, provided that GPIIb/IIIa inhibitors are administered if complications occur during the procedure.

LONG-TERM TREATMENT OF ACUTE CORONARY SYNDROMES

In patients with acute coronary syndromes, long-term treatment with aspirin leads to a reduction in the relative risk of recurrent ischemic events of approximately 23 percent.^{21,22} The addition of vitamin K antagonists further reduces cardiovascular complications, but at the expense of more bleeding.^{21,22} Long-term treatment with low-molecular-weight heparin does not offer an additional benefit over aspirin alone.^{21,22,38} The role of DTIs for long-term secondary prophylaxis in patients also receiving aspirin was investigated in the Efficacy and Safety of the Oral Direct Thrombin Inhibitor Ximelagatran in Patients with Recent Myocardial Damage (ESTEEM) trial.²⁶ Ximelagatran in four oral doses was compared with placebo in patients with myocardial infarction. Ximelagatran significantly reduced the incidence of the combined outcome of all-cause mortality, nonfatal myocardial infarction, and severe recurrent ischemia during the six-month treatment period as compared with placebo, without a dose-response effect. The use of ximelagatran was not associated with a rate of serious bleeding higher than that of aspirin alone, but the total risk of bleeding was higher and dose-related. Elevation of alanine aminotransferase of more than three times the upper limit of normal occurred in 11 percent of the patients treated with ximelagatran and in 2 percent of those receiving placebo.

In summary, the investigation of the role of ximelagatran in the long-term treatment of acute coronary syndromes is limited to one phase 2 trial that was promising with respect to efficacy but identified possible hepatic toxicity as an important concern.

Thus, at present, ximelagatran should not be considered for long-term treatment after acute coronary syndromes.

ATRIAL FIBRILLATION

The most serious clinical complication of atrial fibrillation is ischemic stroke.³⁹ Although aspirin is the treatment of choice for low-risk patients, vitamin K antagonists are preferred for high-risk patients since there is a 36 percent reduction in the relative risk of stroke as compared with aspirin.³⁹

Ximelagatran was compared with dose-adjusted warfarin for the prevention of all strokes and systemic embolism in patients with nonvalvular atrial fibrillation and at least one additional risk factor in the trials called Stroke Prevention Using an Oral Thrombin Inhibitor in Atrial Fibrillation III (SPORTIF III) and SPORTIF V.^{27,28} These two studies had an identical design, except that the SPORTIF III trial was open-label, whereas the SPORTIF V trial was double-blinded. Ximelagatran was observed to be as effective as warfarin with respect to the primary efficacy outcome of stroke or systemic embolism. Furthermore, ximelagatran conferred a significantly lower risk of serious bleeding in the pooled analysis. Ximelagatran was associated with a significant increase in the proportion of patients with alanine aminotransferase levels at least three times the upper limit of normal as compared with warfarin (6.1 percent vs. 0.8 percent).

On the basis of the SPORTIF trials, ximelagatran might be a convenient alternative for vitamin K antagonists in patients who have atrial fibrillation plus at least one additional risk factor. However, the safety of this management strategy remains to be determined.

OTHER INDICATIONS

Recently, data have become available from phase 2 studies on the efficacy and safety of argatroban in acute stroke⁴⁰ and bivalirudin in coronary artery bypass surgery.⁴¹ However, these studies included small numbers of patients and will not be discussed further.

PREVENTION OF VENOUS THROMBOEMBOLISM

Despite prophylaxis, the rate of symptomatic venous thromboembolism in patients undergoing serious orthopedic surgery remains as high as 1.5 to 10 percent in the three months following surgery.⁴² De-

sirudin, melagatran, and ximelagatran have been studied in phase 3 trials in patients undergoing hip or knee surgery (Table 3). Recently, a pilot study investigated the role of the combination of melagatran and ximelagatran in elective abdominal surgery.⁵³

XIMELAGATRAN

Oral ximelagatran has been investigated either alone or in combination with subcutaneous melagatran for the prevention of venous thromboembolism after orthopedic surgery. In a double-blind, randomized trial among patients undergoing total hip replacement, the efficacy and safety of initiating oral ximelagatran after surgery, as compared with enoxaparin, were evaluated.⁴³ The rates of both overall venous thromboembolism and proximal deep venous thrombosis (with or without pulmonary embolism) were significantly higher in patients receiving ximelagatran than they were among those treated with enoxaparin; the incidence of episodes of serious bleeding was similar.

Warfarin (with the use of a target international normalized ratio of 2.5) has been the control treatment in two phase 3 trials among patients undergoing total knee replacement.^{44,45} Both treatments were started postoperatively. In the first study, the incidence of overall venous thromboembolism and proximal deep venous thrombosis (with or without symptomatic pulmonary embolism) was not significantly lower in patients receiving ximelagatran; the incidence of serious bleeding was similar in the two groups.⁴⁴ In the second trial, two doses of ximelagatran were compared with warfarin in order to demonstrate superiority of the higher ximelagatran dose.⁴⁵ A dose of 36 mg of ximelagatran reduced the rate of overall deep venous thrombosis as compared with both 24 mg of ximelagatran and warfarin. Serious bleeding occurred with a similar frequency in all groups. Elevations of alanine aminotransferase that were more than three times the upper limit of normal were observed less frequently with both doses of ximelagatran than with warfarin at the end of treatment, though the levels had normalized in the warfarin group four to six weeks later, whereas persistent increases in levels of alanine aminotransferase were observed in some patients in the ximelagatran groups (0.6 percent and 0.1 percent in the high- and low-dose groups, respectively).

MELAGATRAN—XIMELAGATRAN

The efficacy of the use of subcutaneous melagatran followed by oral ximelagatran was tested in two

Table 3. Clinical Studies Comparing Direct Thrombin Inhibitors with Control Therapy for Prophylaxis and Treatment of Venous Thromboembolism.

Study	Diagnosis or Treatment	No. of Patients	DTI Regimen	Control Treatment	Primary Efficacy Outcomes	Results for Efficacy Outcomes (percentage)	Serious Bleeding (percentage)
Postoperative initiation of prophylaxis							
Colwell et al. ⁴³	Total hip replacement	1838	Ximelagatran at 24 mg twice daily for 7–12 days	Enoxaparin for 7–12 days	Proximal deep venous thrombosis with or without pulmonary embolism	Ximelagatran, 3.6; enoxaparin, 1.2	Ximelagatran, 0.8; enoxaparin, 0.9
Francis et al. ⁴⁴	Total knee replacement	680	Ximelagatran at 24 mg twice daily for 7–12 days	Warfarin for 7–12 days	Overall venous thromboembolism	Ximelagatran, 19.2; warfarin, 25.7	Ximelagatran, 1.7; warfarin, 0.9
EXULT A ^{45*}	Total knee replacement	1851	Ximelagatran at 36 mg and 24 mg twice daily for 7–12 days	Warfarin for 7–12 days	Overall venous thromboembolism or death	Ximelagatran (36 mg), 20.3; ximelagatran (24 mg), 24.9; warfarin, 27.6	Ximelagatran (36 mg), 0.8; ximelagatran (24 mg), 0.8; warfarin, 0.7
METHRO III ⁴⁶	Total hip replacement or total knee replacement	2788	Melagatran subcutaneously at 3 mg, followed by ximelagatran at 24 mg twice daily for 8–11 days	Enoxaparin for 8–11 days	Total venous thromboembolism†	Melagatran–ximelagatran, 31.0; enoxaparin, 27.3	Melagatran–ximelagatran, 1.4; enoxaparin, 1.7
BISTRO II ⁴⁷	Total hip replacement or total knee replacement	1973	Dabigatran at 50 mg, 150 mg, or 225 mg twice daily or 300 mg once daily for 6–10 days	Enoxaparin for 6–10 days	Overall venous thromboembolism	Dabigatran (50 mg), 28.5; dabigatran (150 mg), 17.4; dabigatran (225 mg), 13.1; dabigatran (300 mg), 16.6; enoxaparin, 24.0	Dabigatran (50 mg), 0.3; dabigatran (150 mg), 4.1; dabigatran (225 mg), 3.8; dabigatran (300 mg), 4.7; enoxaparin, 2.0
Preoperative initiation of prophylaxis							
EXPRESS ⁴⁸	Total hip replacement or total knee replacement	2835	Melagatran subcutaneously at 2 mg/hr before surgery and 3 mg/hr after surgery, followed by ximelagatran at 24 mg twice daily for 8–11 days	Enoxaparin for 8–11 days	Serious venous thromboembolism‡	Melagatran–ximelagatran, 2.3; enoxaparin, 6.3	Melagatran–ximelagatran, 3.3; enoxaparin, 1.2
Eriksson et al. ⁴⁹	Total hip replacement	2079	Desirudin at 15 mg subcutaneously twice daily for 8–12 days	Enoxaparin for 8–12 days	Overall deep venous thrombosis	Desirudin, 18.4; enoxaparin, 25.5	Desirudin, 1.9; enoxaparin, 2.0
Eriksson et al. ⁵⁰	Total hip replacement	445	Desirudin at 15 mg subcutaneously twice daily for 8–11 days	Unfractionated heparin for 8–11 days	Overall deep venous thrombosis	Desirudin, 7; unfractionated heparin, 23	No cases of serious bleeding
Initial treatment							
THRIVE ⁵¹	Acute deep venous thrombosis	2489	Ximelagatran at 36 mg twice daily for 6 mo	Enoxaparin–warfarin	Total recurrent venous thromboembolism	Ximelagatran, 2.1; enoxaparin–warfarin, 2.0	Ximelagatran, 1.3; enoxaparin–warfarin, 2.2
Long-term secondary prophylaxis							
THRIVE III ⁵²	Venous thromboembolism	1233	Ximelagatran at 24 mg twice daily for 18 mo	Placebo for 18 mo	Recurrent venous thromboembolism	Ximelagatran, 2.8; placebo, 12.6	Ximelagatran, 1.1; placebo, 1.3

* DTI denotes direct thrombin inhibitor, EXULT A Exanta (Ximelagatran) Used to Lessen Thrombosis A, METHRO III Melagatran for Thrombin Inhibition in Orthopedic Surgery III, BISTRO II Boehringer Ingelheim Study in Thrombosis II, EXPRESS Expanded Prophylaxis Evaluation Surgery Study, and THRIVE Thrombin Inhibitor in Venous Thromboembolism.

† Total venous thromboembolism includes deep venous thrombosis, fatal or nonfatal pulmonary embolism, and unexplained death.

‡ Serious venous thromboembolism includes proximal deep venous thrombosis, symptomatic pulmonary embolism, and death in which pulmonary embolism cannot be ruled out.

phase 3 trials among patients undergoing total hip or total knee replacement.^{46,48} In the Melagatran for Thrombin Inhibition in Orthopedic Surgery III (METHRO III) study, postoperative initiation of melagatran followed by ximelagatran was compared with preoperative initiation of enoxaparin.⁴⁶ Both groups in the study were associated with similar rates of venous thromboembolism and of serious bleeding. In the Expanded Prophylaxis Evaluation Surgery Study (EXPRESS), the administration of melagatran before surgery followed by ximelagatran was compared with preoperative administration of enoxaparin.⁴⁸ The rates of venous thromboembolism were significantly lower with the melagatran–ximelagatran regimen, but both serious and minor bleeding were observed more frequently.

DESIRUDIN

Two phase 3 trials have evaluated preoperative administration of desirudin among patients undergoing hip replacement.^{49,50} In one study, desirudin was compared with preoperative administration of enoxaparin.⁴⁹ The incidence of overall and proximal deep venous thrombosis was lower in patients treated with desirudin, with a similar risk of serious bleeding in the two groups. In the other study, preoperative administration of desirudin was compared with preoperative administration of unfractionated heparin.⁵⁰ Desirudin reduced the incidence of overall and proximal deep venous thrombosis. Serious bleeding episodes were similar in the two groups.

DABIGATRAN

The Boehringer Ingelheim Study in Thrombosis II (BISTRO II) trial, a phase 2 study, compared oral dabigatran with enoxaparin in the prevention of venous thromboembolism after orthopedic surgery.⁴⁷ Dabigatran was started 1 to 4 hours after surgery, whereas enoxaparin was initiated 12 hours before surgery. The highest doses of dabigatran were associated with a significantly lower incidence of venous thromboembolism than was enoxaparin. However, the risk of serious bleeding with dabigatran increased in a dose-dependent manner.

PERIOPERATIVE TIMING

The timing for the initiation of thromboprophylaxis relative to surgery might be more important with the administration of DTIs than with low-molecular-weight heparin, although, to our knowledge, a direct comparison has not been performed.⁴² The

administration of ximelagatran alone or combined with subcutaneous melagatran postoperatively appears to be less effective than low-molecular-weight heparin but more effective than warfarin, with similar bleeding risks. In the administration of preoperative prophylaxis, both desirudin and the combination of melagatran and ximelagatran were observed to be more effective than either unfractionated or low-molecular-weight heparin.⁴⁸⁻⁵⁰ However, the reduction in thromboembolic events with either ximelagatran or melagatran was offset by more bleeding episodes.

Current data, taken together, suggest no important advantages to using most DTIs as compared with the routine use of low-molecular-weight heparin for prophylaxis of venous thromboembolism. The one exception appears to be desirudin, which can be recommended for prophylaxis among patients undergoing hip replacement.

TREATMENT OF ESTABLISHED VENOUS THROMBOEMBOLISM

INITIAL TREATMENT

Phase 2 studies with recombinant hirudin and melagatran have consistently suggested a similar efficacy and safety of DTIs as compared with standard treatment with low-molecular-weight heparin plus vitamin K antagonists for the initial treatment of venous thromboembolism.^{54,55} In the phase 3 Thrombin Inhibitor in Venous Thromboembolism (THRIVE) study, patients with deep venous thrombosis were randomly assigned to receive either six months of oral ximelagatran or initial treatment with subcutaneous enoxaparin combined with warfarin.⁵¹ Ximelagatran was as effective as the combination therapy, and rates of bleeding complications were similar. However, alanine aminotransferase levels increased to more than three times the upper limit of normal in 9.6 percent of the patients receiving ximelagatran and in 2.0 percent of those treated with the combination of enoxaparin and warfarin. Thus, oral ximelagatran was as effective for the treatment of venous thromboembolism without the need for monitoring, but there was concern about safety, given increases in hepatic enzymes.

LONG-TERM SECONDARY PROPHYLAXIS

After six months of treatment with vitamin K antagonists, patients with venous thromboembolism have a 5 to 7 percent risk of recurrence in the first year after discontinuation.⁵⁶ Therefore, long-term

treatment has been recommended for patients at high risk for recurrence. Extended prophylaxis with ximelagatran was compared with placebo for 18 months in patients with thromboembolism who had been treated with vitamin K antagonists for at least 6 months.⁵² Ximelagatran significantly reduced the rate of recurrent venous thromboembolism without a significant increase in the incidence of either serious or minor bleeding. However, ximelagatran was associated with a significantly increased rate of elevated alanine aminotransferase levels (6.4 percent vs. 1.2 percent). Thus, there is concern about hepatic toxicity with long-term use of ximelagatran.

HEPARIN-INDUCED THROMBOCYTOPENIA

Heparin-induced thrombocytopenia is an adverse drug reaction mediated by the immune system, with clinical manifestations initiated by antibodies directed against platelet factor 4, which becomes an antigenic target when bound to heparin. This antibody–platelet factor 4–heparin complex is able to activate platelets and may cause venous and arterial thrombosis. Although the immediate discontinuation of heparin is mandatory in this condition, the strategy is insufficient, given the high cumulative risk of thrombosis during 30-day administration of the drug — up to 53 percent without antithrombotic treatment.⁵⁷ Thus, for patients with suspected or confirmed heparin-induced thrombocytopenia, the use of alternative anticoagulants is recommended.⁵⁷ The use of DTIs for this condition is theoretically supported by the intense thrombin activity observed in these patients.⁵⁷⁻⁵⁹

Two DTIs, lepirudin and argatroban, are approved in the United States for heparin-induced thrombocytopenia. The data about the efficacy and safety of lepirudin and argatroban come from prospective cohort studies that used historical controls.⁵⁹⁻⁶¹ In patients with proven heparin-induced thrombocytopenia who were treated with lepirudin, a thrombotic event occurred in approximately 4 percent of patients, as compared with 15 percent in historical controls, but the administration of lepirudin was associated with a higher rate of serious bleeding (14 percent vs. 8 percent).⁵⁹ Similar results were reported for patients with heparin-induced thrombocytopenia with thromboembolic complications.⁶² In two series of patients with a clinical diagnosis of heparin-induced thrombocytopenia

and thrombosis who were treated with argatroban, the rates of new thrombotic episodes were 13 and 19 percent, as compared with approximately 35 percent in historical controls, with bleeding rates of 6 and 11 percent.^{60,61}

Antihirudin antibodies develop in 40 to 74 percent of patients receiving lepirudin after four days or more of treatment.^{59,63,64} Of note, fatal anaphylaxis has been described with lepirudin, particularly in patients who are treated again within three months of a previous exposure to this agent.⁶⁵ In contrast, argatroban does not appear to be immunogenic.⁶⁶ Thus, lepirudin and argatroban appear to be effective in patients with heparin-induced thrombocytopenia, but drawbacks are an enhanced risk of bleeding and immunogenicity of lepirudin.

REMAINING ISSUES

DIRECT THROMBIN INHIBITORS AND LIVER FUNCTION

No available data report about hepatic dysfunction with the use of recombinant hirudins, bivalirudin, or argatroban. The pharmacokinetic and pharmacodynamic properties of ximelagatran and melagatran do not appear to be influenced in the presence of mild-to-moderate impairment of liver function,⁶⁷ and short-term exposure to ximelagatran (about 12 days) does not appear to increase the risk of hepatotoxicity.⁶⁸ However, data on longer-term use of ximelagatran and melagatran indicate that alanine aminotransferase levels can become elevated after one to six months in 6 to 10 percent of patients. Although increases that have been reported so far are usually asymptomatic and reversible, even if the medication is continued, the few cases of fatal hepatotoxicity observed with prolonged administration of ximelagatran have led the FDA to deny approval of ximelagatran in the United States,⁶⁹ and only short-term use of ximelagatran has been approved in Europe.⁷⁰ The mechanisms of these liver-enzyme abnormalities are still unknown.

MONITORING ACTIVITY

The best method to monitor therapy with DTIs has not been clearly established.⁷¹⁻⁷⁶ The usefulness of the activated partial-thromboplastin time seems limited by its poor linearity and reproducibility, especially when heparin or a vitamin K antagonist is coadministered.^{71-73,77-79} The ecarin clotting time better reflects the actual plasma concentration of DTIs, but this test is not widely available.^{74-77,80-82}

Recombinant hirudins and argatroban can be monitored with the use of the activated partial-thromboplastin time and bivalirudin with the activated clotting time. In patients with heparin-induced immune thrombocytopenia, antihirudin antibodies form complexes with lepirudin that may reduce the renal clearance of the drug.⁶³ This phenomenon often results in a need to reduce and monitor the dose to maintain the lepirudin anticoagulant effect within the therapeutic range, especially in patients with impaired renal function.⁵⁷

Since there is no antidote for rapidly reversing the effect of DTIs, monitoring these drugs is important for patients who have a high risk of bleeding. However, given the short half-life of most DTIs, the major anticoagulant effects of DTIs should have disappeared by 12 to 24 hours after the last dose. Preliminary data suggest that recombinant factor VIIa has a limited capacity to reverse the anticoagulant effects of melagatran.⁸³

CONCLUSIONS

Despite many well-performed clinical trials, there are few clinical indications for DTIs. For acute coronary syndromes, none of the DTIs have consistent-

ly shown superior efficacy combined with a similar safety in comparison with the present standard treatment with heparin and antiplatelet agents. For patients with unstable angina who are undergoing a percutaneous coronary intervention, bivalirudin may be superior to heparin plus GPIIb/IIIa inhibitors administered in case of intraprocedural complications. No DTIs have been convincingly demonstrated to be efficacious and safe for long-term treatment after acute coronary syndromes. In contrast, the efficacy data of ximelagatran in atrial fibrillation are promising, but concern with regard to hepatic toxicity with long-term use must be resolved. When thromboprophylaxis is initiated after serious orthopedic surgery, ximelagatran-containing regimens are less effective than is treatment with low-molecular-weight heparin, but such regimens are superior to warfarin therapy and have a similar safety profile. Preoperative initiation of desirudin is an alternative to the standard approach, but preoperative initiation of melagatran plus ximelagatran increases the risk of bleeding.

Dr. Büller reports having received consulting fees from Astra-Zeneca.

We are indebted to Dr. Ron J.G. Peters, Department of Cardiology, Academic Medical Center, Amsterdam, for critical review of the manuscript.

REFERENCES

1. Tulinsky A. Molecular interactions of thrombin. *Semin Thromb Hemost* 1996;22: 117-24.
2. Liaw PCY, Becker DL, Stafford AR, Frendenburgh JC, Weitz JI. Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin. *J Biol Chem* 2001;276:20959-65.
3. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. *J Clin Invest* 1990;86:385-91.
4. Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. *Circulation* 1998;97:544-52.
5. Bates SM, Weitz JI. The mechanism of action of thrombin inhibitors. *J Invasive Cardiol* 2000;12:Suppl F:27F-32F.
6. Rydel TJ, Ravichandran KG, Tulinsky A, et al. The structure of a complex of recombinant hirudin and human α -thrombin. *Science* 1990;249:277-80.
7. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW II. Design and characterization of Hirulogs: a novel class of bivalent peptide inhibitors of thrombin. *Biochemistry* 1990;29:7095-101.
8. Parry MA, Maraganore JM, Stone SR. Kinetic mechanism for the interaction of Hirulog with thrombin. *Biochemistry* 1994;33: 14807-14.
9. Banner DW, Hadvary P. Inhibitor binding to thrombin: x-ray crystallographic studies. *Adv Exp Med Biol* 1993;340:27-33.
10. Hauptmann J, Sturzebecher J. Synthetic inhibitors of thrombin and factor Xa: from bench to bedside. *Thromb Res* 1999;93: 203-41.
11. Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. *Thromb Haemost* 1994;72:381-6.
12. Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. *Thromb Res* 2003;109:Suppl 1:S9-S15.
13. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. *Circulation* 1998; 97:251-6.
14. Sarich TC, Wolzt M, Eriksson UG, et al. Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. *J Am Coll Cardiol* 2003;41:557-64.
15. Fischer KG. Hirudin in renal insufficiency. *Semin Thromb Hemost* 2002;28: 467-82.
16. Robson R, White H, Aylward P, Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose and gender. *Clin Pharmacol Ther* 2002;71:433-9.
17. Chew DP, Bhatt DL, Kimball W, et al. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. *Am J Cardiol* 2003;92: 919-23.
18. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. *Pharmacotherapy* 2000; 20:318-29.
19. Clarke RJ, Mayo G, FitzGerald GA, FitzGerald DJ. Combined administration of aspirin and a specific thrombin inhibitor in man. *Circulation* 1991;83:1510-8.
20. Fager G, Cullberg M, Eriksson-Lepkowska M, Frison L, Eriksson UG. Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct

- thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid. *Eur J Clin Pharmacol* 2003;59:283-9.
21. Harrington RA, Becker RC, Ezekowitz M, et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004;126:Suppl 3:513S-548S.
22. Menon V, Harrington RA, Hochman JS, et al. Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004;126:Suppl 3:549S-575S.
23. The Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. *Lancet* 2002;359:294-302.
24. White H, Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. *Lancet* 2001;358:1855-63.
25. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. *JAMA* 2003;289:853-63. [Erratum, *JAMA* 2003;289:1638.]
26. Wallentin L, Wilcox RG, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. *Lancet* 2003;362:789-97.
27. Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. *Lancet* 2003;362:1691-8.
28. Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. *JAMA* 2005;293:690-8.
29. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. *Circulation* 1999;100:1602-8.
30. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. *Lancet* 2001;358:605-13.
31. Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. *JAMA* 2004;292:89-96.
32. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. *N Engl J Med* 1995;333:764-9.
33. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. *Am Heart J* 2001;142:952-9.
34. Cohen DJ, Lincoff AM, Lavelle TA, et al. Economic evaluation of bivalirudin with provisional glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. *J Am Coll Cardiol* 2004;44:1792-800.
35. Lincoff AM, Kleiman NS, Kereiakes DJ, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. *JAMA* 2004;292:696-703.
36. Saw J, Lincoff AM, DeSmet W, et al. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy. *J Am Coll Cardiol* 2004;44:1194-9.
37. Chew DP, Lincoff AM, Gurm H, et al. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). *Am J Cardiol* 2005;95:581-5.
38. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. *Lancet* 2000;355:1936-42. [Erratum, *Lancet* 2000;356:600.]
39. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004;126:Suppl 3:429S-456S.
40. LaMonte MP, Nash ML, Wang DZ, et al. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study. *Stroke* 2004;35:1677-82.
41. Merry AF, Raudkivi PJ, Middleton NG, et al. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. *Ann Thorac Surg* 2004;77:925-31.
42. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004;126:Suppl 3:338S-400S.
43. Colwell CW Jr, Berkowitz SD, Davidson BL, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement: a randomized, double-blind study. *J Thromb Haemost* 2003;1:2119-30.
44. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind trial. *Ann Intern Med* 2002;137:648-55.
45. Francis CW, Berkowitz SD, Comp PC, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. *N Engl J Med* 2003;349:1703-12.
46. Eriksson BI, Agnelli G, Cohen AT, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. *Thromb Haemost* 2003;89:288-96.
47. Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. *J Thromb Haemost* 2005;3:103-11.
48. Eriksson BI, Agnelli G, Cohen AT, et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. *J Thromb Haemost* 2003;1:2490-6.
49. Eriksson BI, Wille-Jørgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. *N Engl J Med* 1997;337:1329-35.
50. Eriksson BI, Ekman S, Lindbratt S, et al. Prevention of thromboembolism with use of recombinant hirudin: results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. *J Bone Joint Surg Am* 1997;79:326-33.
51. Fiessinger J-N, Huisman MV, Davidson BL, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. *JAMA* 2005;293:681-9.
52. Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. *N Engl J Med* 2003;349:1713-21.
53. Bergqvist D, Solhaug J-H, Holmdahl L, et al. Pharmacokinetics, preliminary efficacy

- cy and safety of subcutaneous melagatran and oral ximelagatran: a multicenter study of thromboprophylaxis in elective abdominal surgery. *Clin Drug Invest* 2004;24:127-36.
54. Schiele F, Lindgaerde F, Eriksson H, et al. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial. *Thromb Haemost* 1997;77:834-8.
55. Eriksson H, Eriksson UG, Frison L, et al. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. *Thromb Haemost* 1999;81:358-63.
56. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004;126:Suppl 3:401S-428S.
57. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004;126:Suppl 3:311S-337S. [Erratum, *Chest* 2005; 127:416.]
58. Boshkov LK, Warkentin TE, Hayward CP, Andrew M, Kelton JG. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. *Br J Haematol* 1993; 84:322-8.
59. Lubenow N, Eichler P, Lietz T, Farner B, Greinacher A. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. *Blood* 2004;104:3072-7.
60. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. *Circulation* 2001;103:1838-43.
61. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. *Arch Intern Med* 2003;163:1849-56.
62. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. *Blood* 2000;96:846-51.
63. Eichler P, Friesen H-J, Lubenow N, Jaeger B, Greinacher A. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. *Blood* 2000;96:2373-8.
64. Huhle G, Hoffmann U, Song X, Wang LC, Heene DL, Harenberg J. Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment. *Br J Haematol* 1999;106:195-201.
65. Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. *Circulation* 2003;108:2062-5.
66. Walenga JM, Ahmad S, Hoppensteadt D, Iqbal O, Hursting MJ, Lewis BE. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. *Thromb Res* 2002;105:401-5.
67. Wahlander K, Eriksson-Lepkowska M, Frison L, Fager G, Eriksson UG. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. *Clin Pharmacokinet* 2003;42:755-64.
68. Food and Drug Administration Cardiovascular and Renal Advisory Committee. Integrated Executive Summary of FDA review for NDA 21-686 Exanta (ximelagatran), September 10, 2004. (Accessed August 11, 2005, at http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4069B1_03_FDA-Background-Execsummaryredacted.pdf.)
69. AstraZeneca receives action letter from FDA for EXANTA (ximelagatran). Press release from AstraZeneca International, October 11, 2004. (Accessed August 11, 2005, at <http://www.astrazeneca.com/pressrelease/3285.aspx>.)
70. Successful outcome of the mutual recognition procedure for EXANTA (ximelagatran) in Europe. Press release from AstraZeneca International, May 4, 2004. (Accessed August 11, 2005, at <http://www.astrazeneca.com/pressrelease/1898.aspx>.)
71. Fenyvesi T, Jorg I, Harenberg J. Monitoring of anticoagulant effects of direct thrombin inhibitors. *Semin Thromb Hemost* 2002;28:361-8.
72. Moser M, Ruef J, Peter K, et al. Ecarin clotting time but not aPTT correlates with PEG-hirudin plasma activity. *J Thromb Thrombolysis* 2001;12:165-9.
73. Nurmohamed MT, Berckmans RJ, Morrien-Salomons WM, et al. Monitoring anticoagulant therapy by activated partial thromboplastin time: hirudin assessment: an evaluation of native blood and plasma assays. *Thromb Haemost* 1994;72:685-92.
74. Callas DD, Hoppensteadt D, Iqbal O, Fareed J. Ecarin clotting time (ECT) is a reliable method for the monitoring of hirudins, argatroban, efegatran and related drugs in therapeutic and cardiovascular indications. *Ann Hematol* 1996;1:A58. abstract.
75. Callas DD, Fareed J. Comparative anticoagulant effects of various thrombin inhibitors, as determined in the ecarin clotting time method. *Thromb Res* 1996;83:463-8.
76. Radziwon P, Breddin HK, Esslinger H-U. Ecarin time is more suitable to monitor PEG-hirudin treatment compared to APTT, TT, ACT, or aIIa-activity. *Ann Hematol* 1996;1:A57. abstract.
77. Walenga JM, Hoppensteadt D, Koza M, Pifarre R, Fareed J. Comparative studies on various assays for the laboratory evaluation of r-hirudin. *Semin Thromb Hemost* 1991; 17:103-12.
78. Marbet GA, Verstraete M, Kienast J, et al. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers. *J Cardiovasc Pharmacol* 1993;22:364-72.
79. Schenk JE, Glusa E, Radziwon P, Butti A, Markwardt F, Breddin HK. A recombinant hirudin (IK-HIR02) in healthy volunteers. I. Effects on coagulation parameters and bleeding time. *Haemostasis* 1996;26:140-9.
80. Casserly IP, Kereiakes DJ, Gray WA, et al. Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration. *Thromb Res* 2004; 113:115-21.
81. Faaij RA, van Griensven JMT, Schoemaker RC, et al. The effect of warfarin on the pharmacokinetics and pharmacodynamics of napsagatran in healthy male volunteers. *Eur J Clin Pharmacol* 2001;57:25-9.
82. Cho L, Kottke-Marchant K, Lincoff AM, et al. Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentrations. *Am J Cardiol* 2003;91:1110-2.
83. Wolzt M, Levi M, Sarich TC, et al. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. *Thromb Haemost* 2004;91:1090-6.

Copyright © 2005 Massachusetts Medical Society.

CORRECTION

Direct Thrombin Inhibitors

Direct Thrombin Inhibitors . On page 1029, in Figure 1, the arrow pointing from activated protein C and protein S to factors IXa and VIIIa should have been dashed (indicating an inhibitory pathway), rather than solid (indicating an activation pathway). Also, a dashed-line arrow should have been pointing from activated protein C and protein S to factors Xa and Va, rather than the reverse, as printed. These corrections to the figure appear with the full text of the article at www.nejm.org.